Doliprane's Future Uncertain Amid Sanofi's Controversial Sale

Sanofi's decision to sell its Doliprane-producing subsidiary to an American fund raises supply and employment concerns in France.

Doliprane remains the most prescribed medication in France, with over 300 million boxes prescribed in a year.
The drug's popularity is partly due to French regulations preventing pharmacists from substituting it with generics.
Sanofi plans to sell its subsidiary Opella, which produces Doliprane, to the American fund CD&R, sparking political and union opposition.
Concerns center around potential impacts on employment and the supply chain, as the paracetamol used in Doliprane is imported.
The French government has imposed conditions on the sale to ensure production and employment remain in France, though critics find these measures insufficient.